⌕
Allogene Therapeutics · ALLO · Nasdaq
Tenet 65 · Solid
Compare
$0.70−6.48%At closeTenet 65 · Solid
$0.70−0.05 (−6.48%)
At close: Nov 18, 2026, 4:00 PM ET· Nasdaq · USD

Allogene Therapeutics (ALLO) Income Statement

Is this a real, growing, cash-generative business, or a story propped up by accounting?

Sources Company filings FilingsHow we compute thisNot investment advice

12 figures withheld by our checks. Each blank figure names its reason.

Business engineChoppy: revenue is 100% below its peak (through FY24), net margin −1170863.6%. Worth your attention in FY25: Share count (+62.4%). Visible in the receipts below.
The four lines that matter · FY21–FY25
Revenue ($M)—
0.0
FY21→FY25CAGR —
Net income ($M)▲25.9%
−190.9
FY21→FY25CAGR —
Free cash flow ($M)▲25.6%
−149.6
FY21→FY25CAGR —
Diluted EPS▲34.1%
−0.87
FY21→FY25CAGR —
What the receipts whisper · what a headline number hides
Share count
+62.4%

135.8mn → 220.6mn diluted shares since FY21. Rising share count dilutes EPS. Growth must outrun it.

Capex
$386.0K

−44.4% YoY in FY25.

What the income statement says · FY21–FY25
Where every revenue dollar goes · FY25 ($M)0.0Revenue0.0COGS0.0Gross profit−150.2R&D−56.8SG&A−209.3Op income18.4Tax & other−190.9Net income

Margin trend · direction beats level Operating Net
108530%sector median net margin ~3%FY21FY25

This filer reports no gross profit line, so that margin is not drawn.

The receipt · income statement · FY21–FY25 USD thousands except per-share & ratios · hover a line for its definition
The annual and quarterly statements are struck on share counts that differ by a factor of 0.6375, so per-share figures cannot be compared across the two tables. Each table's per-share figures are on its own share basis.
USD thousands except per-share & ratios
Line itemTTM †FY25FY24FY23FY22FY21YoYCAGR 21→25
Revenue & profitability
Revenue
4,640.00.022.095.0156.0114,089.0——
Cost of revenue
—0.00.00.00.00.0——
Gross profit
—A0.0—A—A—A—A——
Research & development
133,290.0150,152.0192,299.0242,914.0256,387.0220,176.0▼21.9%−9.1%
Selling, general & admin
61,559.056,781.065,205.071,673.079,305.074,105.0▼12.9%−6.4%
Total operating expenses
194,849.0209,315.0273,221.0327,832.0335,692.0294,281.0▼23.4%−8.2%
Operating incomefeeds ROC rank
−190,209.0−209,315.0−273,199.0−327,737.0−335,536.0−180,192.0▲23.4%—
Other income, net
15,746.018,429.016,052.0472.0−4,878.0−1,859.0——
Pretax income
−174,463.0−190,886.0−257,147.0−327,265.0−340,414.0−182,051.0▲25.8%—
Income tax
—0.0443.00.0————
Net incomePiotroski ROA ✕feeds Buffett Quality owner earnings
−174,463.0−190,886.0−257,590.0−327,265.0−340,414.0−182,051.0▲25.9%—
Per share
Diluted EPSbuyback-sensitive
−0.63−0.87−1.32−2.09−2.38−1.34▲34.1%—
Diluted shares (mn)
346.09220.62194.81156.93143.15135.82▲13.2%+12.9%
Margins
Gross margin
—A——A—A—A—A——
Operating margin
−4099.3%—−1241813.6%−344986.3%−215087.2%−157.9%——
Net margin
−3760.0%—−1170863.6%−344489.5%−218214.1%−159.6%——
† TTM = trailing four quarters through 2026-09-30.A Withheld: cost of revenue is not on file, so the gross margin is not measured.
FY18 – FY20 · 3 more years
Unlock the full history →
3 more years of statements and CSV export are on Premium.Premium · $119/yr · 7-day trial · cancel anytimeUnlock with Premium →
Annual report filed 2026-03-12 · view filings on SEC EDGAR ↗ · reported currency USD · as-filed figures may be later restated.
Statements normalized in our fundamentals DB · Not investment advice.
Annual and quarterly statements as filed, normalized into one comparable shape · Not investment advice.

Install Tenet on your phone

Tenet home pageMethodology© 2026 Tenet Investing Inc.

Data from Intrinio and Financial Modeling Prep.